VistaGen Therapeutics Inc (VTGN)

NASDAQ
2.780
+0.040(+1.46%)
After Hours
2.790
+0.010(+0.36%)
- Real-time Data
  • Volume:
    1,156,111
  • Bid/Ask:
    2.720/2.840
  • Day's Range:
    2.650 - 2.810

VTGN Overview

Prev. Close
2.74
Day's Range
2.65-2.81
Revenue
1.08M
Open
2.78
52 wk Range
0.555-3.55
EPS
-0.4
Volume
1,156,111
Market Cap
532.04M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,922,867
P/E Ratio
-
Beta
0.92
1-Year Change
265.33%
Shares Outstanding
191,382,350
Next Earnings Date
Aug 17, 2021
What is your sentiment on VistaGen Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

VistaGen Therapeutics Inc News

VistaGen Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyNeutralSellBuy
Technical IndicatorsSellStrong BuyBuyStrong SellStrong Buy
SummaryNeutralStrong BuyNeutralStrong SellStrong Buy

VistaGen Therapeutics Inc Company Profile

VistaGen Therapeutics Inc Company Profile

Employees
21

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company’s CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company’s CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.

Read More
  • This stock is worth 100 usd but trading at 2
    2
    • VistaGen: Patience Could Lead To Significant Upside https://seekingalpha.com/article/4400577-vistagen-patience-lead-to-significant-upside
      2
      • Trending nicely .. breakout soon!!
        0
        • look below i said load up below 80 cents
          0
          • izea
            0
          • Bill Iannellianything new
            0
          • what about MLNTQ?
            0
        • Its not done at all! Going up soon?
          0
          • I guess thats it then?
            0
            • load up below 80
              0
              • sell now drop tomorrow. rebuy
                3
                • tomorrow
                  1
                • Bill Iannellihow far down is it going to go?
                  0
                • told you. went to 82. now 93 this morning. Good daily support at 80 and then rises
                  0
              • what do you think of this set up today
                0
                • to the moon
                  0
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.